16th April 2026 – NICE decision on funding Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474] In development Reference number:GID-TA11613 Expected publication date: 21 May 2026 Final draft guidance After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on Cabozantinib for treating advanced neuroendocrine tumours … Continue reading CABOMETYX® (cabozantinib) for pNET and epNET